Dual-target CD19/BCMA CAR-T cell therapy in systemic lupus erythematosus and myasthenia gravis: current evidence and future directions

Khaled W.D. Alsenawi, Massa Salahi Alasbahi, Berrin Erdağ
Clinical Immunology Communications · Elsevier · DOI: 10.1016/j.clicom.2026.100145

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles